Secondary hypertriglyceridemia.

Hipertrigliceridemias secundarias.
Hipertrigliceridemia secundaria Lipoproteínas de muy baja densidad Metabolic syndrome Secondary hypertriglyceridemia Síndrome metabólico Very low-density lipoprotein

Journal

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
ISSN: 1578-1879
Titre abrégé: Clin Investig Arterioscler
Pays: Spain
ID NLM: 9208512

Informations de publication

Date de publication:
May 2021
Historique:
received: 21 01 2021
accepted: 14 02 2021
entrez: 19 5 2021
pubmed: 20 5 2021
medline: 17 12 2021
Statut: ppublish

Résumé

Secondary hypertriglyceridemia (HTG) are the most common cause of excess triglyceride rich particles in plasma. Faced with HTG, the first thing to do is rule out if there is a secondary cause since it can interact with genetic susceptibility and further aggravate the HTG. The most common causes are diet with high fat and high glycemic index, obesity, diabetes mellitus, alcohol consumption, renal disease like nephrotic syndrome, hepatic disorders and medications. The most important medications that can influence in HTG are oestrogen, isotretinoin, immunosuppressant therapy, L-asparaginase and with less effect thiazides, beta blockers, atypical antipsychotics and glucocorticoids. Other causes less frequent are endocrinological diseases such as Cushing's syndrome, acromegaly, hypothyroidism; pregnancy, lipodystrophies and autoimmune diseases. Lastly, the identifications and treatment or correction of secondary causes is a corner stone in the treatment of this disease.

Identifiants

pubmed: 34006351
pii: S0214-9168(21)00039-5
doi: 10.1016/j.arteri.2021.02.006
pii:
doi:

Substances chimiques

Triglycerides 0

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

29-36

Informations de copyright

Copyright © 2021 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

Clara Viñals (C)

Servicio Endocrinología y Nutrición, Hospital Clínic de Barcelona, Barcelona, España.

Daniel Zambón (D)

Servicio Endocrinología y Nutrición, Hospital Clínic de Barcelona, Barcelona, España; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España.

Gema Yago (G)

Servicio Endocrinología y Nutrición, Hospital Clínic de Barcelona, Barcelona, España.

Mònica Domenech (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN). Instituto de Salud Carlos III (ISCIII), Madrid, España.

Emilio Ortega (E)

Servicio Endocrinología y Nutrición, Hospital Clínic de Barcelona, Barcelona, España; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN). Instituto de Salud Carlos III (ISCIII), Madrid, España. Electronic address: eortega1@clinic.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH